Experimental cancer drug ZW171 tested in 32 patients, but study stopped early

NCT ID NCT06523803

Terminated Disease control Sponsor: Zymeworks BC Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new drug called ZW171 in 32 people with advanced ovarian, lung, or other cancers that have a protein called mesothelin. The main goals were to check the drug's safety and find the right dose. The study was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm non-small cell lung carcinoma ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MESOTHELIN-EXPRESSING ADVANCED CANCERS

Contacts and locations

Locations

Guys and St Thomas' NHS Foundation Trust

London, SE1 9RT, United Kingdom
Icahn School of Medicine at Mount Sinai (ISMMS) - The Blavatnik Family-Chelsea Medical Center

New York, New York, 10011, United States
Norton Cancer Institute

Louisville, Kentucky, 40202, United States
Royal Marsden Hospital

Sutton, SW3 6JJ, United Kingdom
Samsung Medical Center

Seoul, 06351, South Korea
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
Seoul National University Hospital

Seoul, 03080, South Korea
The Catholic University of Korea, Seoul St. Marys Hospital

Seoul, South Korea
The Christie NHS Foundation Trust

Manchester, M20 4BX, United Kingdom
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
Universitaetsklinikum Dresden

Dresden, 01307, Germany
University of Colorado Health Sciences Center

Aurora, Colorado, 80045, United States
University of Southern California - Norris Comprehensive Cancer Center

Los Angeles, California, 90089, United States
University of Washington

Seattle, Washington, 98195, United States
Yonsei University Health System - Severance Hospital

Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.